PAVmed Q2: Veris Accelerates OSU Rollout, Lucid Lands First EsoGuard Coverage Policy
PAVM sits 27% above its 52-week low of $3.85 on elevated volume (4.6× avg).
Summary
PAVmed reported Q2 2026 results with $7.1M operating expenses and a $5.5M GAAP net loss, while cash stands at $3.8M. The company highlighted Veris Health's accelerated commercial engagement with OSU-The James and progress toward an early 2027 FDA 510(k) submission for its implantable physiological monitor. Lucid Diagnostics secured its first laboratory benefit manager coverage policy for EsoGuard, a key reimbursement milestone. PortIO first-in-human results published in the Journal of Vascular Access showed 100% device patency and no device-related adverse events. The 10-Q filed yesterday already disclosed the going concern warning and covenant amendment requiring a $5M deposit by Aug 25, so the financial distress is known; today's release adds operational updates and the coverage policy. The conference call at 8:30 AM ET may provide additional color on the cash runway and FDA timelines. The company reported a second-quarter loss per share of 87 cents.
At the time of this announcement, PAVM was trading at $4.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.9M. The 52-week trading range was $3.85 to $28.44. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.